bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version lifemine therapeutics inc  company profile  biocentury publications archives bciq conferences version  free trial  subscribe sign in english   한국어 biocentury menu home  publications  publications home  biocentury bc innovations bc extra bc week in review current issues archives  archives home  basic search advanced search back issues bciq  bciq home  overview pipeline analyst financial analyst company analyst deal analyst conferences  conferences home  newsmakers bio€quity europe future leaders china healthcare summit other industry events elearning  elearning home  videos white papers follow us bciq  company profile bciq overview      settings      support biocentury print this       lifemine therapeutics inc print preview export bookmark share with colleague general information  location cambridge mass  region new england  country us  business category other  year founded   website  lead product status nd  archive items are loading  financial information  financing summary  financing details  earnings summary  stocks annual chart  pipeline information  pipeline summary  pipeline details  deals information  deals summary  deals details about biocentury company overview management editorial  research contact contact us advertising  sponsorship career opportunities support forgot password customer service reprints faqs products  solutions products overview publications archives bciq conferences elearning rss feeds legal user agreement terms of use privacy policy your california privacy rights use of images follow us what is biocentury biocentury employs a fully integrated multimedia platform — including publications video online data solutions and conferences — to provide its audience with authoritative and uptodate intelligence about corporate strategy partnering emerging technology clinical data public policy and the financial markets sign in free trial   biocentury inc all rights reserved    terms  conditions  privacy policy set email alert dummy lifeline therapeutics inc changes name to lifevantage corporation nasdaqlfvn             share this on delicious digg facebook linkedin twitter what is this « previous release  next release » december   lifeline therapeutics inc changes name to lifevantage corporation denver colorado – lifevantage corporation otcbb lflt maker of protandim® today announced that at its annual meeting of shareholders held on november   shareholders approved amended and restated articles of incorporation that included a name change to lifevantage corporation  we are pleased to be able to change our name to lifevantage  said stephen k onody chief executive officer of lifevantage  all of us at lifevantage believe that our new name better articulates the companys vision and dedication to helping people reach their health and wellness goals with sciencebased natural solutions about protandim® protandim® is a patentpending dietary supplement that increases the bodys natural antioxidant protection by inducing two protective enzymes superoxide dismutase sod and catalase cat  these naturally occurring enzymes become overwhelmed by free radicals as we get older  oxidative stress cell damage caused by free radicals occurs as a person ages when subjected to environmental stresses or as an associated factor in certain illnesses  tbars are laboratory markers for oxidative stress in the body  data from a peerreviewed published scientific study in men and women sponsored by lifevantage show that after  days of taking protandim® the level of circulating tbars decreased an average of  percent with this decrease shown to be maintained at  days  protandim® strengthens a persons defenses against oxidative stress by increasing the bodys natural antioxidant enzymes  for more information please visit the protandim® product web site at wwwprotandimcom about lifevantage corporation lifevantage corporation markets protandim®  lifevantage is committed to helping people achieve health and wellness for life  for more information please visit the companys web site at wwwlifevantagecom except for historical information contained herein this document contains forwardlooking statements within the meaning of the private securities litigation reform act of  applicable common law and securities and exchange commission rules  the company uses the words anticipate believe could should estimate expect intend may predict project plan target and similar terms and phrases including references to assumptions to identify forwardlooking statements  these forwardlooking statements are based on the companys current expectations and beliefs concerning future events affecting the company and involve known and unknown risks and uncertainties that may cause the companys actual results or outcomes to be materially different from those anticipated and discussed herein  these risks and uncertainties are difficult to predict accurately and may be beyond the control of the company  the following factors are among those that may cause actual results to differ materially from our forwardlooking statements  government regulators and regulations could adversely affect our business future laws or regulations may hinder or prohibit the production or sale of our existing product and any future products unfavorable publicity could materially hurt our business and the value of your investment and the companys ability to protect our intellectual property rights and the value of our product  these and other additional risk factors and uncertainties are discussed in greater detail in the companys annual report on form ksb under the caption risk factors and in other documents filed the company from time to time with the securities and exchange commission  forwardlooking statements made by the company in this news release or elsewhere speak only as of the date made  new uncertainties and risks come up from time to time and it is impossible for the company to predict these events or how they may affect the company  the company has no duty to and does not intend to update or revise the forwardlooking statements in this news release after the date it is issued  in light of these risks and uncertainties investors should keep in mind that the results events or developments disclosed in any forwardlooking statement made in this news release may not occur    contacts lifevantage corporation stephen k onody ceo gerald j houston cfo telephone  fax  close window  back to top delicious digg facebook linkedin twitter copyright  lifevantage corp lifemine therapeutics inc private company information  bloomberg july    pm et life sciences tools and services company overview of lifemine therapeutics inc snapshot people company overview lifemine therapeutics inc engages in drug discovery and development using fungi the company was incorporated in  and is based in cambridge massachusetts  acorn park driveth floorcambridge ma united statesfounded in  phone  key executives for lifemine therapeutics inc dr gregory l verdine phd president and executive director age  ms weiqing zhou executive director dr hingge hsu md mba executive director age  compensation as of fiscal year  similar private companies by industry company name region x genomics inc united states g clinical inc united states aapharmasyn llc united states abiant inc united states abiobot inc united states recent private companies transactions typedate target private placement september    request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact lifemine therapeutics inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close massbio career center post a job career center home job view company profile company profile lifemine therapeutics company overview lifemine therapeutics inc is the first biotechnology company exploiting the unique ability of fungi to produce powerful drugs optimized through billions of years of evolution and deploying these molecules for the treatment of intractable human diseases via novel biological mechanisms the company is using a genome mining and recombinant overexpression approach to mount a massive search for novel drugs through the fungal biosphere with operations in cambridge massachusetts manhattan and shanghai lifemine brings a unique global approach to its revolutionary scientific and medical mission basic information subsidiaries  founded  employees  ceo gregory verdine industry biotechnology location cambridge ma us positions available sort by position ▲ date location show all details  day ago senior director bioinformatics lifemine therapeutics  manhattan ny united states save lifemine therapeutics inc is the first biotechnology company exploiting the unique ability of fungi to produce powerful drugs optimized through billions of years of evolution and deploying these molecules for the treatment of intractable human diseases via novel biological mechanisms the company is using a genome mining and recombinant overexpression approach to mount a massive search for novel drugs through the fungal biosphere with operations in cambridge massachusetts and manhattan  see full job description  days ago scientist genomics lifemine therapeutics  manhattan ny united states save company descriptionlifemine therapeutics inc is the first biotechnology company exploiting the unique ability of fungi to produce powerful drugs optimized through billions of years of evolution and deploying these molecules for the treatment of intractable human diseases via novel biological mechanisms the company is using a genome mining and recombinant overexpression approach to mount a massive search for novel drugs through the fungal biosphere with operations in cambridge massachusetts  see full job description  days ago structural biologybiochemist sra lifemine therapeutics  manhattan ny united states save lifemine therapeutics inc is the first biotechnology company exploiting the unique ability of fungi to produce powerful drugs optimized through billions of years of evolution and deploying these molecules for the treatment of intractable human diseases via novel biological mechanisms the company is using a genome mining and recombinant overexpression approach to mount a massive search for novel drugs through the fungal biosphere with operations in cambridge massachusetts and manhattan  see full job description  days ago scientist microbiology lifemine therapeutics inc  manhattan ny united states save lifemine therapeutics inc is the first biotechnology company exploiting the unique ability of fungi to produce powerful drugs optimized through billions of years of evolution and deploying these molecules for the treatment of intractable human diseases via novel biological mechanisms the company is using a genome mining and recombinant overexpression approach to mount a massive search for novel drugs through the fungal biosphere with operations in cambridge massachusetts and manhattan  see full job description  days ago accounts payable specialist lifemine therapeutics  cambridge massachusetts united states save lifemine therapeutics inc is the first biotechnology company exploiting the unique ability of fungi to produce powerful drugs optimized through billions of years of evolution and deploying these molecules for the treatment of intractable human diseases via novel biological mechanisms the company is using a genome mining and recombinant overexpression approach to mount a massive search for novel drugs through the fungal biosphere with operations in cambridge massachusetts and manhattan  see full job description viewing    of  jobs    × insert additional messaging here lifemine therapeutics inc  financing  newest sec filings newest filings lifemine therapeutics inc  financing lifemine therapeutics inc just submitted form d announcing  debt equity financing this is a new filing lifemine therapeutics inc was able to sell  that is  of the round of financing the total private offering amount was  the financing was made by  investors minimal accepted investment was  the financing document was filed on  lifemine therapeutics inc is based in  first street th fl suite  cambridge  the firms business is pharmaceuticals the firms revenue range is decline to disclose the form was signed by gregory verdine sec form d the securities and exchange commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and completethe reader should not assume that the information is accurate and complete united states securities and exchange commissionwashington dc form dnotice of exempt offering of securities omb approval omb number  estimated average burden hours per response   issuers identity cik filer id number previous names    none entity type  lifemine biotherapeutics inc x corporation    limited partnership    limited liability company    general partnership    business trust    other specify name of issuer lifemine therapeutics inc jurisdiction of incorporationorganization delaware year of incorporationorganization    over five years ago x within last five years specify year     yet to be formed  principal place of business and contact information name of issuer lifemine therapeutics inc street address  street address   first street th fl suite  city stateprovincecountry zippostalcode phone number of issuer cambridge massachusetts    related persons last name first name middle name verdine gregory l street address  street address  co lifemine therapeutics inc  first street th fl suite  city stateprovincecountry zippostalcode cambridge massachusetts  relationship x executive officer x director    promoter clarification of response if necessary last name first name middle name zhou weiqing street address  street address  co lifemine therapeutics inc  first street th fl suite  city stateprovincecountry zippostalcode cambridge massachusetts  relationship x executive officer x director    promoter clarification of response if necessary last name first name middle name hsu hingge street address  street address  co lifemine therapeutics inc  first street th fl suite  city stateprovincecountry zippostalcode cambridge massachusetts  relationship x executive officer x director    promoter clarification of response if necessary  industry group    agriculture banking  financial services    commercial banking    insurance    investing    investment banking    pooled investment fund is the issuer registered as an investment company under the investment company act of     yes    no    other banking  financial services    business services energy    coal mining    electric utilities    energy conservation    environmental services    oil  gas    other energy health care    biotechnology    health insurance    hospitals  physicians x pharmaceuticals    other health care    manufacturing real estate    commercial    construction    reits  finance    residential    other real estate    retailing    restaurants technology    computers    telecommunications    other technology travel    airlines  airports    lodging  conventions    tourism  travel services    other travel    other  issuer size revenue range or aggregate net asset value range    no revenues    no aggregate net asset value                                                    over     over  x decline to disclose    decline to disclose    not applicable    not applicable  federal exemptions and exclusions claimed select all that apply    rule b not i ii or iii    rule  bi    rule  bii    rule  biii    rule  x rule b    rule c    securities act section a    investment company act section c    section c    section c      section c    section c    section c    section c    section c    section c    section c    section c    section c    section c    section c  type of filing x new notice date of first sale     first sale yet to occur    amendment  duration of offering does the issuer intend this offering to last more than one year    yes x no  types of securities offered select all that apply x equity    pooled investment fund interests x debt    tenantincommon securities    option warrant or other right to acquire another security    mineral property securities    security to be acquired upon exercise of option warrant or other right to acquire security    other describe  business combination transaction is this offering being made in connection with a business combination transaction such as a merger acquisition or exchange offer    yes x no clarification of response if necessary  minimum investment minimum investment accepted from any outside investor  usd  sales compensation recipient recipient crd number x none associated broker or dealer x none associated broker or dealer crd number x none street address  street address  city stateprovincecountry zippostal code states of solicitation select all that applycheck “all states” or check individual states    all states    foreignnonus  offering and sales amounts total offering amount  usd or    indefinite total amount sold  usd total remaining to be sold  usd or    indefinite clarification of response if necessary  investors    select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors and enter the number of such nonaccredited investors who already have invested in the offering regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors enter the total number of investors who already have invested in the offering   sales commissions  finders fees expenses provide separately the amounts of sales commissions and finders fees expenses if any if the amount of an expenditure is not known provide an estimate and check the box next to the amount sales commissions  usd    estimate finders fees  usd    estimate clarification of response if necessary  use of proceeds provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers directors or promoters in response to item  above if the amount is unknown provide an estimate and check the box next to the amount  usd    estimate clarification of response if necessary signature and submission please verify the information you have entered and review the terms of submission below before signing and clicking submit below to file this notice terms of submission in submitting this notice each issuer named above is notifying the sec andor each state in which this notice is filed of the offering of securities described and undertaking to furnish them upon written request in the accordance with applicable law the information furnished to offerees irrevocably appointing each of the secretary of the sec and the securities administrator or other legally designated officer of the state in which the issuer maintains its principal place of business and any state in which this notice is filed as its agents for service of process and agreeing that these persons may accept service on its behalf of any notice process or pleading and further agreeing that such service may be made by registered or certified mail in any federal or state action administrative proceeding or arbitration brought against it in any place subject to the jurisdiction of the united states if the action proceeding or arbitration a arises out of any activity in connection with the offering of securities that is the subject of this notice and b is founded directly or indirectly upon the provisions of  i the securities act of  the securities exchange act of  the trust indenture act of  the investment company act of  or the investment advisers act of  or any rule or regulation under any of these statutes or ii the laws of the state in which the issuer maintains its principal place of business or any state in which this notice is filed certifying that if the issuer is claiming a regulation d exemption for the offering the issuer is not disqualified from relying on regulation d for one of the reasons stated in rule biii or rule d each issuer identified above has read this notice knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person for signature type in the signers name or other letters or characters adopted or authorized as the signers signature issuer signature name of signer title date lifemine therapeutics inc s gregory l verdine gregory l verdine president  persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid omb number  this undertaking does not affect any limits section a of the national securities markets improvement act of  nsmia pub l no   stat  oct   imposes on the ability of states to require information as a result if the securities that are the subject of this form d are covered securities for purposes of nsmia whether in all instances or due to the nature of the offering that is the subject of this form d states cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent nsmia permits them to do so under nsmias preservation of their antifraud authority lifemine therapeutics inc financing datefiling typeofferedsoldremainingmin investmentinvest countexemption  exlusions new form dbview lifemine therapeutics inc list of executivesgregory verdine hingge hsu weiqing zhou last visited carlyle energy coinvestment iv lp carlyle global financial services partners ii lp carlyle interlink coinvestment lp carlyle red oak coinvestment lp carlyle partners vi lp  lifemine therapeutics inc  pharmaceuticals hsu formdscom  sec filings of fundraisings and investments in hedge funds private equity firms startups and growing companies formdscom newest filter local lifemine therapeutics inc industry pharmaceuticals see others in industry address  first street  th fl suite  cambridge ma phone  filings date filingtype reported sold incremental cash type exemptions link to raw filing  new   equity and debt b sec link directors and executives current and past name role hingge hsu director executive gregory l verdine director executive weiqing zhou director executive ptc therapeutics inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports ptc therapeutics inc  product pipeline review   ptc therapeutics inc  product pipeline review   wgr  september  global  pages global markets direct description table of content sample report enquiry before buy related reports ptc therapeutics inc  product pipeline review   summary global markets direct’s ‘ptc therapeutics inc  product pipeline review  ’ provides an overview of the ptc therapeutics inc’s pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of ptc therapeutics inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of ptc therapeutics inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of ptc therapeutics inc’s human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the ptc therapeutics inc’s pipeline products reasons to buy  evaluate ptc therapeutics inc’s strategic position with total access to detailed information on its product pipeline  assess the growth potential of ptc therapeutics inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the ptc therapeutics inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of ptc therapeutics inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of ptc therapeutics inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of ptc therapeutics inc and identify potential opportunities in those areas  avoid intellectual property rights related issues table of contents table of contents  list of tables  list of figures  ptc therapeutics inc snapshot  ptc therapeutics inc overview  key information  key facts  ptc therapeutics inc – research and development overview  key therapeutic areas  ptc therapeutics inc – pipeline review  pipeline products by stage of development  pipeline products – monotherapy  pipeline products – outlicensed products  outlicensed productscombination treatment modalities  ptc therapeutics inc – pipeline products glance  ptc therapeutics inc – late stage pipeline products  preregistration productscombination treatment modalities  phase iii productscombination treatment modalities  ptc therapeutics inc – clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  ptc therapeutics inc – early stage pipeline products  preclinical productscombination treatment modalities  discovery productscombination treatment modalities  ptc therapeutics inc – drug profiles  ataluren  product description  mechanism of action  rd progress  ptc  product description  mechanism of action  rd progress  ptc  product description  mechanism of action  rd progress  small molecule to activate dystrophin for duchenne muscular dystrophy  product description  mechanism of action  rd progress  small molecules for gramnegative bacterial infections  product description  mechanism of action  rd progress  ptc therapeutics inc – pipeline analysis  ptc therapeutics inc – pipeline products by target  ptc therapeutics inc – pipeline products by route of administration  ptc therapeutics inc – pipeline products by molecule type  ptc therapeutics inc – pipeline products by mechanism of action  ptc therapeutics inc – recent pipeline updates  ptc therapeutics inc – dormant projects  ptc therapeutics inc – discontinued pipeline products  discontinued pipeline product profiles  ataluren  ptc  ptc therapeutics inc – locations and subsidiaries  head office  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables ptc therapeutics inc key information  ptc therapeutics inc key facts  ptc therapeutics inc – pipeline by indication   ptc therapeutics inc – pipeline by stage of development   ptc therapeutics inc – monotherapy products in pipeline   ptc therapeutics inc – outlicensed products in pipeline   ptc therapeutics inc – outlicensed products combination treatment modalities   ptc therapeutics inc – preregistration   ptc therapeutics inc – phase iii   ptc therapeutics inc – phase ii   ptc therapeutics inc – phase i   ptc therapeutics inc – preclinical   ptc therapeutics inc – discovery   ptc therapeutics inc – pipeline by target   ptc therapeutics inc – pipeline by route of administration   ptc therapeutics inc – pipeline by molecule type   ptc therapeutics inc – pipeline products by mechanism of action   ptc therapeutics inc – recent pipeline updates   ptc therapeutics inc – dormant developmental projects  ptc therapeutics inc – discontinued pipeline products   list of figures ptc therapeutics inc – pipeline by top  indication   ptc therapeutics inc – pipeline by stage of development   ptc therapeutics inc – monotherapy products in pipeline   ptc therapeutics inc – outlicensed products in pipeline   ptc therapeutics inc – pipeline by top  target   ptc therapeutics inc – pipeline by top  route of administration   ptc therapeutics inc – pipeline by top  molecule type   ptc therapeutics inc – pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send